Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
I'm PortAI, I can summarize articles.
Maxwell Skor has issued a Buy rating for Cidara Therapeutics, highlighting its antiviral candidate CD388, which targets the $5 billion influenza market. CD388 offers a single-dose prevention option and is expected to show broad protection in Phase 3 data due in June 2026. The drug has received FDA Fast Track and Breakthrough Therapy designations, and positive Phase 2b results support its potential. Cidara's strong financial position enhances its attractiveness as an investment, with J.P. Morgan also initiating coverage with a Buy rating and a $200 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments